Bladder cancer: Atezolizumab effective against advanced-stage disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection.Medicine · 2022
   Trial
2. Tumour cell-released autophagosomes promote lung metastasis by upregulating PD-L1 expression in pulmonary vascular endothelial cells in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2024
   Article
3. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.Molecular cancer therapeutics · 2022
   Article
4. Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.Translational andrology and urology · 2019
   Article
5. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Nature reviews. Urology · 2018
   Review
6. Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.CytoJournal · 2018
   Article
7. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Journal of hematology & oncology · 2017
   Review
8. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?Human vaccines & immunotherapeutics · 2017
   Article
9. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.The Lancet. Oncology · 2017
   Review
10. Anti-PD-1 inhibits Foxp3Cancer immunology, immunotherapy : CII · 2016
    Article
11. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.Nutrients · 2016
    Article
12. Molecular Imaging of Immunotherapy Targets in Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Review

Corrections and comments

• Comment on
  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as